Sign in

    Nikola (Nick) Gasic

    Research Analyst at Leerink Partners

    Nikola (Nick) Gasic is Vice President, Biotechnology Equity Research at Leerink Partners, focused on the biotechnology sector with coverage of companies such as Arcturus Therapeutics, Sensorion, Voyager Therapeutics, and Xenon Pharmaceuticals. Gasic has demonstrated consistent analytical rigor, maintaining positive performance ratings across several covered firms, with recent reports showing strong sector knowledge and actionable investment recommendations. He began his career after earning an undergraduate degree from the University of Toronto and a doctorate in pharmacy, progressing from Associate at Leerink Partners to his current role. Gasic holds a Pharm.D. and is believed to maintain FINRA securities industry credentials as part of his analyst function.

    Nikola (Nick) Gasic's questions to Vir Biotechnology (VIR) leadership

    Nikola (Nick) Gasic's questions to Vir Biotechnology (VIR) leadership • Q1 2025

    Question

    Nikola (Nick) Gasic, on behalf of Roanna Ruiz, asked about VIR's expectations for the 24-week off-treatment data from the MARCH study in HBV, set to be presented at EASL. He also inquired about the potential implications of this data for partnership discussions.

    Answer

    Mark Eisner (Executive) noted that while he could not comment extensively ahead of the presentation, the company had previously signaled a target of a 20% functional cure rate for the doublet and 30% for the triplet. Marianne De Backer (Executive) added that any further development of the HBV program remains contingent on securing a worldwide development and commercialization partner.

    Ask Fintool Equity Research AI